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Abstract
Background: Barriers to care limit the potential benefits of pharmacological intervention for inflammatory arthritis.
A self-administered questionnaire for early inflammatory arthritis (EIA) detection may complement contemporary
triage interventions to further reduce delays to rheumatologic care. The objective of this study was to develop a
self-administered EIA detection tool for implementation in pre-primary care settings.
Methods: A core set of dimensions and constructs for EIA detection were systematically derived from the literature
and augmented by investigative team arbitration. Identified constructs were formulated into lay language
questions suitable for self-administration. A three-round Delphi consensus panel of EIA experts and stakeholders
evaluated the relevance of each question to EIA detection and suggested additional items. Questions accepted by
less than 70% of respondents in rounds one or two were eliminated. In round three, questions accepted by at
least 80% of the panel were selected for the tool.
Results: Of 584 citations identified, data were extracted from 47 eligible articles. Upon arbitration of the literature
synthesis, 30 constructs encompassing 13 dimensions were formulated into lay language questions and posed to
the Delphi panel. A total of 181 EIA experts and stakeholders participated on the Delphi panel: round one, 60;
round two, 59; and, round three, 169; 48 participated in all three rounds. The panel evaluated the 30 questions
derived from the literature synthesis, suggested five additional items, and eliminated a total of 24. The eleven-
question instrument developed captured dimensions of articular pain, swelling, and stiffness, distribution of joint
involvement, function, and diagnostic and family history.
Conclusions: An eleven-question, EIA detection tool suitable for self-administration was developed to screen
subjects with six to 52 weeks of musculoskeletal complaints. Psychometric and performance property testing of the
tool is ongoing.
Background
Barriers to care [1-5] continue to suppress the therapeu-
tic advantages of early pharmacological intervention in
inflammatory arthritis (IA) with disease-modifying anti-
rheumatic drugs (DMARDs) [6-8]. Pronounced barriers
exist along the entire care pathway. Prior to primary
care, patient preferences, psychosocial issues, and inter-
relationship issues with primary care practitioners
(PCPs) may negatively impact health seeking behaviour
[9-11]. In primary care, PCPs have the formidable task
of detecting an IA incidence of 0.05 to 0.2% in the
absence of sensitive laboratory and diagnostic imaging
tests [12,13]. Acute symptomatic response to non-steroi-
dal anti-inflammatory drugs (NSAIDs) and disease pre-
sentation in undifferentiated or spontaneously remitting
forms may further delay diagnosis, referral and treat-
ment [14,15]. In addition, PCPs may have insufficient
musculoskeletal (MSK) training in residency or continu-
ing medical education (CME) opportunities to effectively
detect and manage IA [15-20]. Although rheumatology
referral may be hampered by shortages of rheumatolo-
gists and long referral waiting lists in some regions
[9-11], the majority of the delays to DMARD treatment
occur prior to referral [1].
Several approaches have been developed to minimize
these barriers. These include public awareness programs,
CME programs to improve MSK clinical management in
primary care [21,22], early referral guidelines [14,23-25],
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utilizing patient self-detection has been developed in the
current study.
The objective of this study was to develop a self-admi-
nistered EIA detection tool encompassing dimensions of
stage-one case ascertainment to accelerate access to
appropriate care for IA. The two stages of case ascer-
tainment include 1) detection of suspected cases, and 2)
confirmation of the clinical diagnosis [30]. Clinical
examinations, comprised of history-taking and physical
examination, are used in stage-one. Laboratory and diag-
nostic imaging investigations in EIA are limited to stage-
two due to their high cost and low sensitivity. As a
stage-one case ascertainment intervention, the ap r i o r i
criteria for the EIA detection tool were 1) inclusion of
clinical history and physical examination elements suita-
ble for self-administration, 2) exclusion of items requir-
ing medical intervention to enable pre-primary care self-
assessment, and 3) simplicity and brevity, to render the
tool applicable to a broad demographic.
Methods
Literature Search
A structured literature search was conducted to derive
dimensions and constructs relevant to EIA detection. The
National Library of Medicine citation index, MEDLINE
(1966 to July Week 3, 2006), was searched using a combi-
nation of medical subject headings and keywords: ["exp
Arthritis, Rheumatoid/di” or “exp Spondylarthritis/di” or
“(inflammatory adj1 arthritis).tw.” or “(undifferentiated
adj2 arthritis).tw."] and ["early diagnosis” or “mass screen-
ing” or “exp ‘referral and consultation” or “screen$.tw."]
(Figure 1). A Cochrane Collaboration MSK Group refer-
ence librarian developed and conducted the search strat-
egy. The criteria for article selection included the
investigation of prognostic indicators of EIA, or question-
naires developed for early or established IA detection.
Articles in languages other than English, French or
German were excluded.
Independently, two rheumatologists sequentially
reviewed the citation title, abstract, and full article. At
each stage of the review, where sufficient information
was available to determine the ineligibility of articles,
they were excluded. After the independent selection of
eligible articles, discrepancies were resolved by consen-
sus between the two reviewers. A third-party arbitrator
was selected to settle non-consensus items but did not
need to be used. Data extraction was conducted inde-
pendently by the two reviewers and consensus was used
to resolve discrepancies. The consensus list of dimen-
sions and constructs for EIA detection were extracted
and adjudicated by the investigative team.
The investigative team met to evaluate the relevance
of the identified items to the objective, target popula-
tion, and proposed mode of administration of the tool.
The literature synthesis was supplemented with addi-
tional dimensions and constructs derived from clinical
experience, guidelines for MSK examination [31,32], and
classification criteria for IA [33-35]. The investigative
team arbitrated on the items identified to select dimen-
sions and constructs of stage-one case ascertainment
and to render the tool suitable to self-administration in
pre-primary care settings. Selected items were formu-
lated into grade eight reading level questions using the
Figure 1 Literature search strategy to identify stage-one case ascertainment constructs of early inflammatory arthritis.
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(Redmond, WA). Where available, questions from pre-
existing IA tools were adapted for self-administration in
the current tool [30].
Delphi Consensus Panel
Early inflammatory arthritis health professionals (EIA
experts) were solicited for participation in a three-round
Delphi consensus panel to evaluate the relevance of the
derived questions for EIA detection. Experts were identi-
fied from the literature search, abstracts from the annual
meetings of the ACR, Canadian Rheumatology Associa-
tion (CRA), and EULAR, and through nomination by
participant EIA experts. Members of the ACR, American
College of Family Physicians (AAFP), American College
of Physicians (ACP), Association of Rheumatology
Health Professionals (ARHP), Outcome Measures in
Rheumatology (OMERACT), patient advocacy groups,
and United States Bone and Joint Decade (USBJD) were
solicited for participation as additional stakeholders.
Delphi panel participants evaluated the relevance of
each question to EIA detection ("yes"/"no”), and sug-
gested additional items.
Thresholds for question acceptance by the Delphi
panel were set ap r i o r i : round one, ≥ 0.70; round 2, ≥
0.70; and, round 3, ≥ 0.80. Percent acceptance was used
to assess the true relevance of questions to EIA detec-
tion. In round one, the lower threshold excluded the
least frequently accepted questions. In round two, a
selection of questions below the threshold in round one
was retested to determine the inter-round consistency of
the panel. New questions derived from round one feed-
back were also tested. In round three, questions above
the threshold from rounds one or two were re-evaluated
by the panel. In round three, a higher threshold was
used to minimize the total number of questions while
selecting those of greatest overall relevance.
The primary analysis population included all Delphi
panel participants. The secondary analysis population
included participants of all three rounds of the Delphi
panel. Differences in the acceptance of questions
between the two analysis populations were arbitrated by
the investigative team to derive the EIA detection tool.
Results
The processes of literature synthesis, investigative team
arbitration, and Delphi panel acceptance resulted in the
development of eleven EIA stage-one case ascertainment
questions (Figure 2).
Literature Synthesis
A total of 584 citations were identified from the litera-
ture search strategy. Upon independent review by the
two reviewers and consensus on discrepant selections,
47 articles were selected for the identification of dimen-
sions and constructs for EIA detection. Ten unique
dimensions were derived from the literature synthesis:
demographics; pain; swelling; stiffness; fatigue; nodules;
function; laboratory and diagnostic imaging; genetics;
and, diagnostic history (including constitutional symp-
toms). Thirty-one constructs were identified and cate-
gorized under the derived dimensions. Of these, eleven
specific laboratory and diagnostic imaging tests were
determined to be inappropriate for self-administration
in pre-primary care settings. In place of these, items
regarding a history of having had a “blood test for RA”
and “x-rays of your hands or wrists” were proposed by
the investigative team. Likewise, although physical func-
tion was evaluated as relevant to the detection of EIA,
specific, extensive instruments (e.g. HAQ) were inap-
propriate for a brief self-administered instrument. To
address the dimension of function, a question pertaining
to activities of daily life was proposed. Two specific
genetic factors (HLA B27; HLA DRB1) were replaced
with items pertaining to family history of IA. Psychoso-
cial and socioeconomic dimensions were arbitrated to
be access to care issues and not dimensions of EIA
detection.
Investigative Team Arbitration of Literature Synthesis
Utilizing clinical experience, MSK guidelines, IA classifi-
cation criteria, and pre-existing IA questionnaires, the
investigative team proposed the following additional
dimensions as relevant to EIA detection: treatment his-
tory; characterization of symptom onset; and, distribu-
tion of joint involvement. Additional demographic
constructs included age, recent pregnancy, and recent
weight loss. In total, the investigative team differentiated
13 dimensions of EIA detection, which were captured
by 30 specific constructs. The 30 constructs were for-
mulated into individual, grade eight reading level ques-
tions in second-person narrative. Over the subsequent
three-round Delphi consensus panel, 35 questions
encompassing 13 dimensions were evaluated for their
relevance to EIA detection (Table 1).
Delphi Panel: Participants
A total of 181 EIA experts and stakeholders participated
in the Delphi panel (Figure 3). Thirteen of 64 solicited
EIA experts participated in the Delphi panel and nomi-
nated 13 additional participants. Five of the 13 nomina-
tions participated on the Delphi panel. The investigative
team identified an additional 65 representatives from
stakeholder groups, 42 of which participated in the Del-
phi panel. Over the course of the three-round Delphi
panel, an additional 121 stakeholders participated. Over-
all, nine EIA experts and 39 stakeholders participated in
all three Delphi panels. Delphi panel participants
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Page 3 of 11Figure 2 Study flow diagram. The diagram illustrates the flow of the dimensions, constructs, and derivative questions from a synthesis of the
literature, revisions based on investigative team arbitration, and three-round Delphi consensus panel acceptance. EIA = early inflammatory
arthritis. *Combined into eligibility criteria for tool administration
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Elements and Questions Delphi Round* EIA Tool
(X)
1
(n =
60)
2
(n =
59)
3
(n =
169)
Demographics
1. In which month and year were you born? 66.7 - - -
†
2. What is your gender, male or female? 75.0 - 54.4 -
†
3. If female, have you been pregnant or given birth within the last year? 63.3 - - -
4. Have you smoked or have you been exposed to smoke on a regular basis in your life?
‡ 55.0 54.2 26.6 -
5. Over the past year, have you had more than 10 lbs (5 kg) weight loss without trying? - 57.6 - -
Articular Pain
6. Do you have pain in your joints? 91.7 - 91.1 X
7. Do you have pain in your wrists and hands? 95.0 - 92.3 X
8. Do you have pain in the ball of your foot? 71.7 - 65.7 -
9. Do you have pain in your neck, your back, your buttocks or the muscles in your legs? 63.3 - - -
Articular Swelling
10. Are your hands or wrists swollen? 98.3 - 91.1 X
11. Are your rings still fitting?
‡ 56.7 44.1 - -
12. Do you have trouble with your shoes fitting? 43.3 20.3 - -
Articular Stiffness
13. Do you have trouble making a fist? 93.3 - 85.2 X
14. Are your joints stiff in the morning? 96.7 - 95.3 X
15. Do you have a feeling of back stiffness in the morning?
‡ 61.7 74.6 78.1 -
16. From the time you wake in the morning, how many minutes does it take for your joints to move more
freely, less than 30 minutes or more than 30 minutes?
‡
95.0 - 91.7 X
Distribution of Joint Involvement
17. At any time have your lower limbs been affected, such as your groin knees, ankles, or feet? 63.3 - - -
18. Are the same joints involved on both sides of your body? - 88.1 87.6 X
Characterization of symptom onset
19. For how long have you had these symptoms, less than 1 year or more than 1 year?
‡ 86.7 - 79.3
§ -**
20. Did your bone and joint problem come on suddenly?
‡ - 76.3 80.5 -**
Nodules
21. Have you developed any new lumps or bumps on your arms or legs? 66.7 - - -
Function
22. Have important activities in your life been affected because of bone or joint problems, such as having
difficulty with personal care or having to make a change regarding leisure or work activities?
80.0 - 87.6 X
Fatigue
23. Do you find that you are getting tired earlier in the day than you used to? 68.3 - - -
Laboratory Test and Diagnostic Imaging History
24. Have you had a blood test for rheumatoid arthritis? 75.0 - 63.3 -
25. Have you had x-rays of your hands or wrists? 68.3 - - -
Diagnostic History
26. Have you ever been told that you have rheumatoid arthritis? 88.3 - 72.8
§ X
27. Have you seen an arthritis specialist or rheumatologist in the past year? 80.0 - 71.6 -
28. Have you been diagnosed with a rash called psoriasis? 90.0 - 81.7 X
29. Have you had a recent viral or other infection or illness?
‡ - 76.3 76.9 -
Family History
30. Does anyone in your family have rheumatoid arthritis? 91.7 - 93.5 X
31. Does anyone in your family have a rash called psoriasis? 78.3 - 79.9 -
Treatment History
32. Have you used anti-inflammatory drugs to manage your arthritis? 80.0 - 79.3 -
33. Have you used disease-modifying anti-rheumatic drugs (DMARDS) to manage your arthritis? 71.7 - 65.7 -
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health care disciplines (Table 2).
Delphi Panel: Round one
Thirty questions were posed to the 60 Delphi panel
round one participants. Eighteen questions met the
70% threshold. Five new items were suggested by
round one participants that represented unique con-
structs relating to back stiffness, characterization of
symptom onset, distribution of joint involvement,
infection, and use of medications. Five new questions
were developed by the investigative team and intro-
duced in round two to evaluate the relevance of these
suggestions.
Delphi Panel: Round two
In Round two, ten questions were posed to the panel.
The round two panel was comprised of round one parti-
cipants and one additional nominated participant. Two
members of the round one panel did not respond in
round two. A selection of five of the 12 questions below
the round one threshold and the five new questions
derived from round one suggestions were tested in
round two. Five of the ten questions tested met the
r o u n dt w ot h r e s h o l d( f o u rn e ws u g g e s t i o n sa n do n e
rephrased question from round one). Through rounds
one and two, 23 questions met the 70% threshold and
were re-tested in round three. An additional question
b e l o wt h er o u n do n ea n dt w ot h r e s h o l dw a sr e p h r a s e d
and tested in round three.
Delphi Panel: Round three
A total of 24 questions were evaluated by 169 partici-
pants in the Delphi panel round three. Eleven questions
met the round three threshold as evaluated by all round
three participants. All questions above the threshold in
primary analysis population remained above the thresh-
old in the secondary analysis population. Two additional
questions (Table 1, no. 20 and no. 24) met the round
three threshold in the secondary analysis population
only. Question no. 20 was combined with no. 21 and
introduced as eligibility criteria for tool administration.
The investigative team arbitrated to keep questions no.
24 in the tool.
EIA Detection Tool
The tool included eleven questions encompassing seven
dimensions of EIA detection and captured demographic
characteristics of the target population (Figure 4). The
dimensions captured included articular pain, swelling
and stiffness, distribution of joint involvement, function,
and diagnostic and family history of IA. Two questions
pertained to pain: one general, “Do you have pain in
your joints?"; and one joint-specific, “Do you have pain
in your wrists and hands?”. One question pertained to
swelling: “Are your hands or wrists swollen?”. Stiffness
was captured by three questions: one general, “Do you
have trouble making a fist?"; one pertained to time of
onset, “Are your joints stiff in the morning?"; and one
included duration within the construct, “From the time
you wake in the morning, does it take more than 60
minutes for your joints to move more freely?”.O n e
question pertained to the distribution of joint involve-
ment: “Are the same joints involved on both sides of
your body?”. Physical function was captured by one
question: “Have important activities in your life been
affected because of bone or joint problems, such as hav-
ing difficulty with personal care or having to make a
change regarding leisure or work activities?”. A question
regarding primary care diagnostic history was included:
“Have you ever been told you have rheumatoid arthri-
tis?”.F a m i l yh i s t o r yw a sc a p tured by two questions:
“Does anyone in your family have rheumatoid arthritis?";
and, “Have you been diagnosed with a rash called psor-
iasis?”. The tool also included two eligibility criteria
restricting the detection population to persons with at
least six weeks and less than 52 weeks of musculoskele-
tal symptoms.
Discussion
A self-assessment instrument was developed to promote
primary care health-seeking behaviour and accelerate
the referral of incident cases of IA to rheumatology. The
eleven-question tool captures the dimensions of articular
pain, swelling, and stiffness, distribution of joint involve-
ment, function, and diagnostic and family history. It was
designed for self-administration by persons with six to
52 weeks of MSK complaints. The focus of the current
study was the development of a tool with content and
Table 1: Delphi panel acceptance of questions for an early inflammatory arthritis detection tool (Continued)
34. Have you used non-pharmacological (non-drug) methods to manage your arthritis? 61.7 54.2 - -
35. Do you take pills on a daily basis to make your pain or stiffness feel better? - 79.7 72.8 -
*In rounds 1 and 2, a cut-off of <70% was used to eliminate questions from the EIA detection tool. In round 3, a cut-off of <80% was used.
†Age and gender are captured as demographic assessments on the EIA detection tool.
‡Phrasing of question changed in round two or three.
§85.4% Acceptance by respondents involved in all three rounds of the Delphi panel (secondary analysis population).
**Symptom duration items were modified into eligibility criteria for tool administration. Persons with musculoskeletal complaints for a duration of at least six
weeks but no more than 52 weeks are eligible to self-administer the tool.
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rithm and the tool’s performance and psychometric
properties are ongoing.
The content validity of the EIA detection tool is
assessed in the context of stage-one case ascertainment.
The EIA detection tool directly captures seven of 13
dimensions relevant to EIA detection. Dimensions were
derived by the investigative team to organize data from
the literature synthesis. Constructs were defined as ele-
ments of prognostic factors and clinical measures
requiring formulation into self-assessment questions.
The content of the tool is consistent with the dimen-
sions of clinical examination as described in guidelines
for the assessment of new-onset MSK complaints
[31,32] and classification criteria for IA [33-35].
A l t h o u g ht h e r ei sp a u c i t yi nt h ep r e d i c t i v ev a l i d i t yo f
individual measures of clinical examination [32], these
are clinically relevant measures applicable to stage-one
case ascertainment.
The construct validity of the tool is qualitatively
ascribed by comparisons to IA clinical examination
measures found in classification criteria, early referral
recommendations, prevalence questionnaires, and triage
tools. Two prominent IA classification criteria include
the 1987 ACR criteria for RA [33] and the European
Spondylarthopathy Study Group (ESSG) criteria for SpA
[34]. Although the value of these criteria in the detec-
tion of EIA is questionable [36-39], new criteria directed
at early rheumatoid arthritis detection have been pro-
posed by an ACR/EULAR collaboration and include
joint involvement, symptom duration and serological
markers in its scoring algorithm [40]. Physical examina-
tion constructs from these and other IA criteria [35]
appear in the tool. Questions pertaining to the 1987
ACR criteria constructs of morning stiffness, joint areas
involved, swelling, and symmetry appear in the EIA
detection tool and dimensions of joint pain, stiffness,
swelling, and psoriasis are applicable to the ESSG cri-
teria. Through the Delphi panel, specific laboratory and
diagnostic imaging tests, and items pertaining to
nodules, buttock pain, and constitutional symptoms
were eliminated.
The dimensions and constructs in the tool are also
similar to those captured in prominent early referral to
rheumatology recommendations for IA. The early refer-
ral recommendation for RA includes at least 30 minutes
duration of morning stiffness, at least three swollen
joints, or tenderness of either the metacarpophalangeal
or metatarsophalangeal joints [24]. The early referral
recommendation for ankylosing spondylitis includes
inflammatory back pain, genetic predisposition (HLA
B27), and sacroiliitis [41,42]. With exception to the
laboratory and diagnostic imaging tests applicable to
stage-two case ascertainment, the dimensions of pain,
swelling, and stiffness in the EIA detection tool encom-
pass the clinical examination dimensions in early referral
recommendations for IA conditions. Similarly, there is
some overlap between the EIA detection tool and clini-
cal examination dimensions found in existing inter-
viewer-administered IA prevalence questionnaires and
triage tools [26-29]. Few tools, classification criteria, or
early referral recommendations include health assess-
ment instruments, such as the HAQ or multi-dimen-
s i o n a lH A Q( M D H A Q ) .T or e d u c eq u e s t i o n n a i r e
burden on the population, such tools may be more sui-
table for stage-two case ascertainment as proposed by
Emery [43]. Cumulatively, overlaps between the content
of the EIA detection tool and measures of classifying,
recommending referral of, or triaging IA conditions,
support the construct validity of the tool.
The EIA detection tool encompasses many unique fea-
tures. Foremost, the tool targets the pre-primary care
population, whereas triage tools focus on prioritizing
Figure 3 Delphi consensus panel participant flow diagram.E I A
= early inflammatory arthritis
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instruments, the EIA detection tool offers the potential
advantage of detecting cases that delay or avoid primary
care, or are otherwise not considered for rheumatologic
care. Among IA instruments, the mode of self-adminis-
tration is also unique. The questions have been formu-
lated in lay language, kept brief, and have unidirectional,
dichotomous “yes"/"no” response options. The simplicity
and brevity of the tool are expected to facilitate its
adoption in pre-primary care settings.
The population for the EIA detection tool is restricted
to persons with six to 52 weeks of MSK complaints. As
suggested by preliminary performance testing, this
restriction increases the pre-test probability of IA from
the incidence of 0.05-to-0.2% to 25% (data not pre-
sented). Hypothetically, if the general population was
screened with a tool with 99% sensitivity and 99% speci-
ficity the positive predictive value (PPV) would range
from ten to 30% [44]. With a pre-test probability of EIA
of 25%, a tool with 99% sensitivity and specificity results
in a PPV for EIA that exceeds 95% [44]. Restricting the
population augments the pre-test probability of EIA
cases to a high percentage that improves the perfor-
mance properties of the tool.
Others have applied restrictions as well. The early
referral recommendation for ankylosing spondylitis is
restricted to patients presenting with more than three
months of low back pain and symptom onset prior to
45 years of age [41,42]. Age-based restrictions for breast
cancer, osteoporosis, and other diseases are common
and accepted as well. Despite the acceptable use of
restrictions, the tool may be modified for detecting EIA
Table 2 Delphi consensus panel participant characteristics
Characteristics Overall
(n = 181)
Participants in all 3 Rounds
(n = 48)
Additional Participants
(n = 133)
Gender
Female 59.1 52.1 63.6
Male 40.9 47.9 36.4
Country/Region of practice
United States of America 37.0 8.3 9.1
Canada 35.4 8.3 2.5
Romania 7.7 6.3 9.1
Austria 6.1 0.0 6.6
United Kingdom 4.4 4.2 4.1
Australia 3.9 4.2 4.1
Turkey 2.2 2.1 2.5
Spain 1.7 2.1 1.7
Switzerland 1.7 2.1 1.7
Primary discipline
Rheumatologist 38.1 31.2 40.6
Physical/Occupational Therapy 19.9 18.8 20.3
Patient Advocate 13.8 2.1 18.0
Other Physician* 12.7 14.6 12.0
Physician Assistant/Nurse Practitioner 12.2 25.0 7.5
Rheumatology Nurse 3.3 8.3 1.5
Career Stage
†
Mid career 67.9 63.8 71.1
Late career 32.1 36.2 27.8
Urban or Rural
†
Urban 85.3 87.2 84.5
Rural 14.7 12.8 14.4
Majority of Time Spent
†
Clinical 67.9 59.6 74.2
Academic 32.1 40.4 25.8
Primary Work Setting
†
Institutional 73.7 68.1 76.3
Private Practice 26.3 31.9 23.7
*Family medicine, physical medicine and rehabilitation, internal medicine and paediatrics
†Characteristics not applicable to patient advocates.
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requirements currently included as restrictions may by
re-introduced as questions, i.e. “Have you had [joint or
back pain, swelling or stiffness] for more than six
weeks?” and “Have you had [joint or back pain, swelling
or stiffness] for less than one year?”. Only respondents
answering “yes” to both conditional questions, would be
further evaluated for EIA. This strategy would leverage
the advantages of pre-test probability augmentation and
simplify field implementation.
Some unique dimensions were not selected for the tool
due to not meeting the Delphi panel threshold. Although
symptomatic response to NSAIDs has been reported as a
prognostic indicator of IA [14,35], the investigative team
refrained from overruling the Delphi panel failure to
accept the NSAID question to avoid the indirect endorse-
ment of ineffective IA treatments. There was insufficient
evidence in the literature for the validity of fatigue as a
dichotomous predictive measure of EIA to overturn the
Delphi panel’s failure to accept the item. In addition,
laboratory and diagnostic imaging tests important in
stage-two were excluded owing to the central aim of
developing a stage-one case ascertainment instrument.
The performance properties of this tool are outstand-
ing. Studies to evaluate the performance and psycho-
metric properties of the EIA detection tool are
underway. The intra-rater reliability, internal consis-
tency, and discriminant validity are currently being
tested. A scoring algorithm to optimize the sensitivity,
specificity, and positive and negative predictive values of
the tool is also being investigated. Ultimately, an evalua-
tion of the tool’s psychometric, and performance prop-
erties, is required to support the content and construct
validity reported in the current study.
Conclusions
A self-administered tool with content and construct
validity has been developed for stage-one case ascertain-
ment of EIA. The tool includes eleven brief, simple lan-
guage questions evaluated as relevant by a high
percentage of EIA experts and stakeholders. Its self-
assessment design allows it to be implemented pre-pri-
mary care, where the greatest impact of reducing delays
to care is expected.
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